Press Releases

20242023202220212020201920182017201620152014
Date
Press Release
17th December 2024
Inventiva to present at the 43rd Annual J.P. Morgan Healthcare Conference
16th December 2024
Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 million
12th December 2024
Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024
21st November 2024
Inventiva reports 2024 Third Quarter Financial Information
20th November 2024
Combined General Meeting of December 11, 2024 – Availability of the preparatory documents
20th November 2024
Statement of total voting rights and shares forming the company’s share capital as of November 4th, 2024
15th November 2024
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
30th October 2024
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
21st October 2024
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
14th October 2024
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
14th October 2024
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
14th October 2024
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
25th September 2024
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results
31st July 2024
Inventiva Reports Preliminary 2024 First-Half Financial Information
25th July 2024
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor
18th July 2024
Inventiva announces a €20.1 million issuance of royalty certificates
5th July 2024
Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position
21st June 2024
Description of The Share Repurchase Program Authorised by The Ordinary General Meeting of 20 June 2024
21st June 2024
Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024
30th May 2024
Combined General Meeting of June 20, 2024 – Availability of the preparatory documents
22nd May 2024
Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024
21st May 2024
Inventiva reports 2024 First Quarter Financial Information and provides a corporate update
16th May 2024
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH
13th May 2024
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor
3rd April 2024
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
28th March 2024
Inventiva announces the nomination of Andre Turenne as Director
27th March 2024
Inventiva reports its 2023 full-year results
22nd March 2024
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
18th March 2024
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
13th March 2024
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
7th March 2024
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed
15th February 2024
Inventiva reports preliminary 2023 fiscal year financial information and provides an update on its clinical trial NATiV3
24th January 2024
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
10th January 2024
Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank
Date
Press Release
20th December 2023
Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program
4th December 2023
Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH
21st November 2023
Inventiva reports 2023 Third Quarter Financial Information
6th November 2023
Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023
28th September 2023
Inventiva reports its 2023 first-half financial results and provides a corporate update
20th September 2023
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
31st August 2023
Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates
27th July 2023
Inventiva Reports Preliminary 2023 First-Half Financial Information and Business update
22nd March 2023
Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association
13th June 2023
Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD
8th June 2023
Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients
7th June 2023
Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023
26th May 2023
Results of the votes of the Combined Shareholders’ General Meeting of May 25, 2023
25th May 2023
Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate the clinical development of lanifibranor in China
25th May 2023
Description of the share repurchase program authorised by the ordinary general meeting of 25 May 2023
16th May 2023
Inventiva reports 2023 First Quarter Financial Information and provides a corporate update
4th May 2023
Statement of total voting rights and shares forming the company’s share capital as of April 17, 2023
4th May 2023
Combined General Meeting of May 25, 2023. Availability of the preparatory documents
30th March 2023
Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F
29th March 2023
Inventiva reports its 2022 Full-Year Results
23rd March 2023
Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results
14th February 2023
Inventiva reports preliminary financial results for Full-Year 2022
26th January 2023
Results of the votes of the Combined Shareholders’ General Meeting of January 25, 2023
4th January 2023
Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis
3rd January 2023
Statement of total voting rights and shares forming the company’s share capital as of December 19, 2022
3rd January 2023
Combined General Meeting of January 25, 2023. Availability of the preparatory documents
Date
Press Release
12th December 2022
Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank
28th November 2022
Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US
21st November 2022
Inventiva announces a new Director of the Board of Directors
10th November 2022
Inventiva reports 2022 Third Quarter Financial Information
31st October 2022
Inventiva provides an update on the development of cedirogant by AbbVie
21st October 2022
Inventiva announces a scientific presentation at the AASLD The Liver Meeting® 2022
22nd September 2022
Inventiva reports its 2022 first-half financial results and provides a corporate update
21st September 2022
Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China
7th September 2022
Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results
28th July 2022
Inventiva Reports 2022 First-Half Financial Information
7th July 2022
Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D
4th July 2022
Update on Inventiva’s cash position and on the finance documentation with the European Investment Bank
16th June 2022
Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022
9th June 2022
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022
7th June 2022
Inventiva joins the Euronext Tech Leaders segment
3rd June 2022
Inventiva announces the presentation of a scientific abstract at the 82nd Scientific Sessions of the American Diabetes Association
23rd May 2022
Inventiva announces participation at several investors conferences in May and June 2022
20th May 2022
Results of the votes of the Combined Shareholders’ Meeting of May 19, 2022
19th May 2022
Description of the share repurchase program authorised by the Ordinary General Meeting of 19 May 2022
16th May 2022
Inventiva reports 2022 First Quarter Financial Information and provides clinical development update
16th May 2022
Inventiva secures a €50 million credit facility from the European Investment Bank
28th April 2022
Combined General Meeting of May 19, 2022 Availability of the preparatory documents
28th April 2022
Statement of total voting rights and shares forming the company’s share capital as of April 11, 2022
7th April 2022
Inventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver
11th March 2022
Inventiva announces filing of its 2021 Universal Registration Document and 2021 Annual Report on Form 20-F
8th March 2022
Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA
7th March 2022
Inventiva reports its 2021 Full-Year Results: key milestones achieved with lanifibranor in NASH and cedirogant in psoriasis
1st March 2022
Inventiva announces participation at several conferences in March 2022
28th February 2022
Inventiva announces the schedule of publication and presentation of its 2021 Full-Year Financial Results
14th February 2022
Inventiva reports cash position and revenues for Full-Year 2021
31st January 2022
Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiation
20th January 2022
Inventiva announces participation at several conferences in January and February 2022
Date
Press Release
16th December 2021
Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference
6th December 2021
Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor
10th November 2021
Inventiva reports 2021 Third Quarter Financial Information
3rd November 2021
Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021
29th October 2021
Inventiva announces participation at several investor conferences in November 2021
27th October 2021
Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes
20th October 2021
The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH
18th October 2021
Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021
28th September 2021
Inventiva announces participation at several investor conferences in October 2021
23rd September 2021
Inventiva completes sale of $30 million through its ATM program to existing and new specialized institutional investors
21st September 2021
Inventiva announces FDA decision that Fast Track designation granted to lanifibranor in NASH encompasses the treatment of NASH with compensated cirrhosis
20th September 2021
Inventiva reports 2021 first half financial results and provides a corporate update
16th September 2021
Inventiva announces major recruitments to accelerate the development of lanifibranor in NASH
10th September 2021
Inventiva’s 2021 First-Half Financial Results Presentation
8th September 2021
Inventiva announces the initiation of its pivotal Phase III clinical trial evaluating lanifibranor in NASH
30th August 2021
Inventiva announces participation at several investor conferences in September 2021
2nd August 2021
Inventiva announces the implementation of an At-The-Market program in the United States
28th July 2021
Inventiva Reports First-Half of 2021 Financial Information
15th June 2021
Inventiva to participate at the SVB Leerink CybeRx Series: Liver Disease Day
9th June 2021
Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2021 and during a KOL webcast event
25th May 2021
Inventiva to participate at the Jefferies Virtual Healthcare Conference
12th May 2021
Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto-immune diseases
26th April 2021
Inventiva to participate at the 7th Annual Truist Securities Life Sciences Summit
19th April 2021
Appointment of Martine Zimmermann as Independent Director to Inventiva’s Board of Directors
25th March 2021
Shareholders Meeting of April 16, 2021 – Availability of the preparatory documents and methods for participating and voting
15th March 2021
Inventiva announces filing of its 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
4th March 2021
2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States
25th February 2021
Inventiva announces collaboration on non-invasive biomarkers to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvement
24th February 2021
Inventiva to participate at several investor conferences in March 2021
23rd January 2021
Inventiva’s 2020 Full-Year Financial Results Presentation
11th February 2021
Full-Year 2020: Cash position and revenues
6th January 2021
Inventiva to present at the 39th Annual J.P. Morgan Healthcare Conference
5th January 2021
Inventiva announces design of Phase III clinical trial with lanifibranor in NASH
Date
Press Release
7th December 2020
Inventiva announces the publication in the Journal of Hepatology of new pre-clinical data showing the beneficial effects of lanifibranor on cirrhosis
24th November 2020
Inventiva to participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference
12th November 2020
Q3 2020 Financial Information
10th November 2020
Inventiva receives positive FDA feedback to advance its lead drug candidate lanifibranor into pivotal Phase III in NASH
9th November 2020
Inventiva to participate at the Stifel Virtual Healthcare Conference 2020 and the 11th Jefferies Virtual Healthcare Conference
5th November 2020
Inventiva announces the appointment of Dr. Michael Cooreman as Chief Medical Officer
2nd November 2020
Inventiva announces the publication of a scientific paper on the role of PPARs in the treatment of NASH in the medical journal Nature Review Gastroenterology & Hepatology
2nd November 2020
Inventiva announces the additional acceptance of two late-breaking abstracts at the AASLD The Liver Meeting Digital Experience™ 2020
28th October 2020
Inventiva to host a Key Opinion Leader webcast from the AASLD The Liver Meeting Digital Experience™ 2020
19th October 2020
Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparcil
12th October 2020
Inventiva receives FDA Breakthrough Therapy designation for lead drug candidate lanifibranor in NASH
5th October 2020
Inventiva selected to present the results of its NATIVE Phase IIb clinical trial with lanifibranor in NASH during a plenary session at The Liver Meeting Digital Experience™ 2020
24th September 2020
Inventiva to participate at several investor conferences in October 2020
16th September 2020
H1 2020 financial results and corporate business update
9th September 2020
Inventiva to participate at several investor conferences in September 2020
15th July 2020
Inventiva announces the closing of $107.7 million initial public offering on the Nasdaq Global Market
10th July 2020
Inventiva annonce la mise à disposition d’un prospectus dans le cadre de son offre au public d’actions ordinaires sous la formes d’ADS à l’occasion de son introduction en bourse sur le Nasdaq Global Market (only in French)
10th July 2020
Inventiva announces trading resumption of its ordinary shares on Euronext Paris
10th July 2020
Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris
10th July 2020
Inventiva announces the pricing of its initial public offering on the Nasdaq Global Market
8th July 2020
Inventiva announces the filing of an amended registration statement, including an estimated initial public offering price range
6th July 2020
Inventiva Announces the Start of the Roadshow for its Proposed Global Offering and Proposed Nasdaq Listing
6th July 2020
H1 2020 Financial Information
6th July 2020
Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2 diabetes patients (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)
19th June 2020
Inventiva files registration statement for proposed initial public offering in the United States
15th June 2020
Inventiva’s lanifibranor meets the primary and key secondary endpoints in the Phase IIb NATIVE clinical trial in non-alcoholic steatohepatitis (NASH)
2nd June 2020
Inventiva to participate at the Jefferies Virtual Healthcare Conference
25th May 2020
Inventiva secures a new patent for lanifibranor in China expanding the protection of its lead product candidate
19th May 2020
Inventiva secures €10.0 m non-dilutive loan facility guaranteed by the French State in the context of the COVID-19 pandemic
18th May 2020
Inventiva’s latest research on odiparcil’s mechanism of action published in leading peer-reviewed scientific journal PLOS ONE
14th May 2020
Q1 2020 Financial Information
6th May 2020
Shareholders Meeting of May 28, 2020 – Availability of the preparatory documents and methods for participating and voting at the meeting
21st April 2020
Inventiva to provide an update on the NATIVE Phase IIb clinical trial in NASH during a Key Opinion Leader webcast
7th April 2020
Inventiva provides a corporate business update in the context of the COVID-19 pandemic
17th March 2020
Inventiva announces completion of patient visits for its Phase IIb clinical study with lanifibranor in NASH
10th March 2020
2019 Full-Year Results: Significant progress in NASH, MPS VI and psoriasis, and extended cash runway
19th February 2020
Inventiva to present at the Cowen and Company 40th Annual Health Care Conference
10th February 2020
Inventiva files a prospectus in the context of the admission to trading of new shares on Euronext Paris
7th February 2020
Inventiva completes a capital increase of €15 m subscribed by existing shareholders
5th February 2020
Full-Year 2019 : Cash position and revenues
3rd February 2020
Inventiva selected to present the positive results from its Phase IIa clinical study with odiparcil in MPS VI at the 16th « Annual WORLDSymposiumTM »
6th January 2020
Inventiva admitted to the SRD “Long only” on the regulated market of Euronext Paris
Date
Press Release
18th December 2019
Inventiva announces positive results from Phase IIa clinical study with odiparcil in mucopolysaccharidosis type VI
3rd December 2019
Inventiva receives a €3.5 m milestone payment from AbbVie
13th November 2019
Q3 2019 financial information and update on the partnership with Boehringer Ingelheim
12th November 2019
Inventiva to present at the Jefferies 2019 London Healthcare Conference
16th October 2019
Inventiva to participate at the H.C. Wainwright 3rd Annual NASH Investor Conference and the Gilbert Dupont NASH Day
30th September 2019
Inventiva completes a capital increase of € 625,000 subscribed by Sofinnova Partners through Sofinnova Crossover I Fund
26th September 2019
Inventiva receives FDA Fast Track designation for lead asset lanifibranor in NASH
25th September 2019
H1 2019 financial results and corporate business update
19th September 2019
Inventiva completes a capital increase of € 8.2 million subscribed by leading US and European biotech investors
10th September 2019
Inventiva announces the positive recommendation of the 4 th and last DSMB of the Phase IIb clinical study with lanifibranor in NASH
4th September 2019
Inventiva achieves a major milestone by completing patient recruitment for its Phase IIb clinical study with lanifibranor in NASH
2nd September 2019
Odiparcil development advances with recruitment of first patients in a new biomarker study in MPS VI children and adults
28th August 2019
Inventiva secures a new European patent strengthening and extending the protection of its lead product candidate lanifibranor
27th August 2019
New promising results on lanifibranor to be presented at The Liver Meeting® 2019
20th August 2019
Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor
30th July 2019
H1 20191 Financial Information and Corporate Business Update
13th June 2019
Inventiva announces the creation of its Scientific Advisory Board
11th June 2019
Inventiva Announces End of Patient Recruitment for its Phase IIa Trial in the Treatment of MPS VI
29th May 2019
Nawal Ouzren and Heinz Maeusli appointed to Inventiva’s Board of Directors
24th May 2019
Inventiva to Present at the Jefferies 2019 Healthcare Conference
23rd May 2019
Inventiva announces that FDA lifts target class clinical hold which allows long-term clinical studies with lanifibranor in NASH
23rd April 2019
Inventiva to present new results of its YAP-TEAD oncology program at the AACR Special Conference on The Hippo Pathway
3rd April 2019
Inventiva to Participate at the H.C. Wainwright Global Life Sciences Conference
6th March 2019
Inventiva to Present Corporate Overview at the Cowen and Company 39th Annual Health Care Conference
5th March 2019
The FDA Grants Rare Pediatric Disease Designation to Odiparcil for the Treatment of MPS VI
21st February 2019
Inventiva announces further progress achieved in the clinical development of lanifibranor for the treatment of NASH
18th February 2019
Inventiva Announces Results From Phase IIb Clinical Trial with Lanifibranor in Systemic Sclerosis
4th February 2019
New results on lanifibranor to be presented at the International Liver Congress™ 2019
Date
Press Release
10th December 2018
Inventiva invited to present at the 37th Annual J.P. Morgan Healthcare Conference
7th November 2018
Inventiva Announces Poster Presentation on Its YAP/TEAD Inhibitor Program at the EORTC-NCI-AACR Symposium in Dublin
30th October 2018
Inventiva invited to present at Stifel 2018 Healthcare Conference in New York and at Jefferies 2018 London Healthcare Conference
17th October 2018
Inventiva announces two appointments to its management team ahead of future key development milestones
15th October 2018
Inventiva Announces Last Visit by Last Patient in its Phase IIb SSc Trial and Second Positive DSMB Review in its Phase IIb NASH Trial with Lanifibranor
12th October 2018
Inventiva to Participate in the “ROTH Battle of the NASH Thrones Investor Conference”
10th October 2018
Inventiva Announces Two Poster Presentations at the American College of Rheumatology Conference
24th September 2018
Inventiva launches an independent working group to help increase NASH awareness and establish best practices for its treatment
30th August 2018
Inventiva advances in the development of lanifibranor with the achievement of three key milestones
29th August 2018
Inventiva to Present at the H.C. Wainwright 20th Annual Global Investment Conference
13th August 2018
Inventiva’s lanifibranor found to have good safety profile following first assessment of carcinogenicity studies’ results
1st August 2018
Inventiva to Present the Latest Findings in its RORγ program at the 256th National Meeting of the American Chemical Society
26th July 2018
Inventiva Announces Poster Presentation on a Promising Biomarker for MPS VI at the 15th International Symposium on MPS and Related Diseases
10th July 2018
Inventiva Announces Positive DSMB Reviews in both NASH and Systemic Sclerosis Phase IIb Trials with Lanifibranor
9th July 2018
Inventiva announces that it has been informed of the modification of the call option agreement concluded by BVF Partners L.P.
20th June 2018
FDA Approval of an Investigator Initiated IND Application to Conduct Phase II Study of Lanifibranor in Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease
11th June 2018
Inventiva to Present at the 2018 JMP Securities Life Sciences Conference
30th May 2018
Inventiva to Present at the Jefferies 2018 Global Healthcare Conference
28th May 2018
Dr Lucy Lu is appointed to the Inventiva Board of Directors
3rd April 2018
Inventiva Announces a U.S. Phase II Investigator-Initiated Study with Lanifibranor on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes
28th March 2018
Lanifibranor carcinogenicity studies: Progressing as planned and interim results in rats indicate no compound related urinary bladder tumors
13th March 2018
Inventiva’s paper on the discovery and synthesis of its panPPAR agonist lanifibranor accepted and published in the Journal of Medicinal Chemistry of the American Chemical Society
8th March 2018
Inventiva to present at six investor conferences in March 2018
27th February 2018
2018 Full-Year Results : Important Progress in R&D Portfolio and Solid Cash Position
26th February 2018
Inventiva announces positive outcomes of biomarker study measuring intracellular GAGs in leukocytes from MPS VI patients
31st January 2018
Inventiva to present in vivo data with odiparcil at the 14th WORLDSymposium™
4th January 2018
Inventiva Announces Positive DSMB Review in Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor
3rd January 2018
Inventiva Announces Enrollment of First Patient into Its Odiparcil Phase IIa Trial (iMProveS) for MPS VI
Date
Press Release
13th November 2017
Inventiva to Present at Two Upcoming Investor Conferences
17th October 2017
Inventiva’s Phase IIb FASST Trial in Systemic Sclerosis with Lanifibranor Completes Enrollment
18th September 2017
Inventiva’s IVA337 Given Generic Name “Lanifibranor” by the World Health Organization (WHO)
5th September 2017
Inventiva announces exercise of option by Boehringer Ingelheim to jointly develop potential new treatments for idiopathic pulmonary fibrosis (IPF)
4th September 2017
Inventiva and AbbVie Extend Agreement to Discover New Potent Orally-Available Small Molecule RORγ Inverse Agonist Drug Candidates
10th August 2017
Odiparcil Awarded Orphan Drug Designation for the Treatment of MPS VI by the FDA
27th July 2017
Inventiva to Present New Data on IVA337 at the 15th International Workshop on Scleroderma Research in Pittsburgh, USA
29th June 2017
Inventiva Announces New Compelling Data on Odiparcil/IVA336 to be Presented at MPS Society National Conference
20th June 2017
Inventiva Announces Peer Review Publication of IVA337 Data in Pre-Clinical NASH Models
6th June 2017
Inventiva to Present at the Jefferies 2017 Global Healthcare Conference
30th May 2017
Dr Nanna Lüneborg, Principal of Novo Ventures, joins Inventiva’s Board
15th May 2017
Inventiva Announces Positive Results of 12 Month Primate Toxicity Study with IVA337
20th April 2017
Inventiva Announces Presentation of Preclinical Results on IVA337 in NASH at the International Liver Congress™ 2017 (EASL)
10th April 2017
Inventiva Hits Clinical Milestone with Enrollment of 100th Patient in IVA337 Phase 2b FASST Trial in Systemic Sclerosis (SSc)
3rd January 2017
Inventiva Announces Initiation of Phase IIb Clinical Trial of IVA337 for Treatment of Non-Alcoholic Steatohepatitis (NASH)

Upcoming Investors Meetings

43rd Annual J.P. Morgan Healthcare conference

From 13th to 16th January 2025
San Francisco

13th edition of Degroof Petercam’s virtual healthcare conference

From 21st to 24th January 2025
Virtual

Upcoming Science Conferences

MASH-TAG Conference

From 9th to 12th January 2025
Park City

Questions?
Get in touch!

Inventiva
Pascaline Clerc
EVP, Strategy and Corporate Affairs
pascaline.clerc@inventivapharma.com
+1 202 499 8937

Brunswick
Tristan Roquet Montegon
Aude Lepreux
Matthieu Benoist
Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

Patti Bank
Managing Director
ICR Westwicke
Patti.Bank@westwicke.com
D 415-513-1284
San Francisco, CA
www.westwicke.com